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apy as a treatment option for cancer, but responses in solid
tumors are hampered by the immunosuppressive microenvi-
ronment. The production of TCR gene-engineered T cells re-
quires full T cell activation in vitro, and it is currently unknown
whether in vivo interactions with conventional dendritic cells
(cDCs) regulate the accumulation and function of engineered
T cells in tumors. Using the B16 melanoma model and the
inducible depletion of CD11c+ cells in CD11c.diphtheria toxin
receptor (DTR) mice, we analyzed the interaction between
tumor-resident cDCs and engineered T cells expressing the
melanoma-speciﬁc TRP-2 TCR. We found that depletion of
CD11c+ cells triggered the recruitment of cross-presenting
cDC1 into the tumor and enhanced the accumulation of
TCR-engineered T cells. We show that the recruited tumor
cDCs present melanoma tumor antigen, leading to enhanced
activation of TCR-engineered T cells. In addition, detailed
analysis of the tumor myeloid compartment revealed that the
depletion of a population of DT-sensitive macrophages can
contribute to the accumulation of tumor-inﬁltrating T cells.
Together, these data suggest that the relative frequency of
tumor-resident cDCs and macrophages may impact the thera-
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The success of cancer immunotherapy in recent years has changed the
way we treat cancer. Therapies that target endogenous adaptive im-
mune responses against tumors in patients, such as antibody blockade
of inhibitory pathways that prevent T cell function, have led to tumor
remission in patients with previously untreatable cancers. However,
the non-speciﬁc nature of this approach may lead to serious side ef-
fects, due to the release of auto-reactive T cells. One alternative to
enhance anti-tumor immunity and reduce auto-reactivity is redirect-
ing the speciﬁcity of T cells using T cell receptors (TCRs) or chimeric
antigen receptors (CARs). The transfer of TCR-modiﬁed T cells spe-
ciﬁc for melanoma-associated antigens has been shown to lead to
clinical responses, including durable tumor regression in a subset of
patients.1–3 However, clinical responses to gene-modiﬁed T cells for
solid tumor cancers have not shown the success of clinical trials for
hematologic malignancies. Improving treatments requires a moreMo
This is an open access article under thdetailed understanding of the cellular interactions that modify
T cell function in solid tumors.
Tumors are populated by different populations of myeloid cells that
express the integrin CD11c. Of these, conventional dendritic cells
(cDCs) are specialized antigen-presenting cells that control T cell im-
munity. Lineage tracing experiments in mice have mapped two devel-
opmentally and functionally distinct populations, cDC1 and cDC2,
that reside in peripheral tissues where they are deﬁned by expression
of CD103 and CD11b, respectively.1 These lineages and their func-
tions are conserved in humans.2–4 Of these, cDC1 are highly efﬁcient
at cross-presenting antigens to cytotoxic T cells and are the major
stimulatory cDC population within tumors, both for the generation
of anti-tumor immunity in draining lymph nodes (LNs) and upon
direct interaction with effector T cells within the tumor microenvi-
ronment.5–8 Furthermore, cDC1 are critical for therapeutic responses
to checkpoint blockade,9–11 but their possible role in modifying the
function of engineered T cells has not been as extensively studied.
Engineering T cells to express TCRs speciﬁc to tumor antigens
commonly uses retro- or lentiviral gene transfer vectors. Transduc-
tion with these vectors depends on T cell activation and proliferation,
which is required for access of genes encoded in the vector into the
nucleus for integration into the host genome. As such, T cells are
routinely activated in vitro using non-speciﬁc mitogens, or stimula-
tion of CD3 and CD28 as part of the transduction protocol, and trans-
ferred as effector-like T cells into hosts. An advantage of this strategy
is that transfer of activated T cells circumvents priming by cDCs,
which may be dysfunctional in the cancer patient.12 But direct inter-
actions between tissue DCs and effector or memory T cells outside
secondary lymphoid organs are also required for T cell functionlecular Therapy Vol. 26 No 6 June 2018 ª 2018 The Authors. 1471
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Figure 1. Characterizing Depletion of CD11c+ Cells from B16 Tumors
(A) Mice were injected subcutaneously (s.c.) with 5  105 B16.F10 cells, and tumors were harvested 17 days later. Representative flow cytometric plots show the gating of
myeloid and cDC populations within tumor-infiltrating leukocytes. Plots are pre-gated on live, single CD45+ cells and shown exclusion of Ly6C+ monocytes (non-mono) to
produce an APC (antigen presenting cell) population that contains F4/80+ macrophages (macs) and cDC populations. (B) Representative plots from an independent
experiment demonstrating that use of a flow cytometry panel in which macrophages are identified with CD64 results in similar population frequencies. (C) Representative
contour plots showing expression of CD24 and F4/80 by pre-gated cDC1 (blue) and cDC2 (yellow). (D) Summary bar graph showing mean frequency of myeloid cell
populations as a proportion of total CD45+ cells in the tumor (±SD); n = 8, from two independent experiments. Mono., monocyte; Macs, F4/80+ macrophages. (E)
CD11c.DTR mice were injected intraperitoneally (i.p.) with 100 ng DT. Bar chart shows the frequency of splenic CD11c+/MHCII+ cDCs (±SD) 48 hr later. p = 0.0002; n = 6,
(legend continued on next page)
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www.moleculartherapy.organd survival,13 and, within the tumor, cDCs directly interact with
effector T cells.8,14 In addition to cDCs, tumors contain populations
of monocytes and macrophages that express varying levels of
CD11c, which are commonly associated with the development of
an immunosuppressive tumor environment through secretion of cy-
tokines such as interleukin 10 (IL-10) or transforming growth factor b
(TGF-b).15 However, the extent to which the number and function of
transduced T cells is affected by CD11c+ cells once they are recruited
to the tumor is not known.
In this study, we have exploited an inducible model of CD11c+ cell
depletion to investigate the impact of CD11c+ cells, including cDCs,
on the fate of T cells engineered to express an H2-Kb-restricted
TCR against the melanoma-associated antigen tyrosinase-related
protein 2 (TRP-2).16 We demonstrate that dynamic interactions
with different myeloid cells control accumulation of transferred
T cells within the changing tumor environment. Depletion of
CD11c+ cells triggered the recruitment of cross-presenting cDC1
into the tumor and a loss of CD11c+ macrophages, resulting in the
accumulation of TRP-2 TCR-engineered T cells. Together, these
data indicate that the balance between tumor-resident cDCs andmac-
rophages impacts the accumulation of TRP-2 TCR-engineered T cells
in B16 tumors.
RESULTS
Characterizing Depletion of CD11c+ Cells from B16 Tumors in
CD11c.DTR Mice
As an initial approach to dissect the role of tumor-resident CD11c+
populations in the activation of TCR gene-modiﬁed T cells, we
analyzed the inducible depletion of cDCs, and other CD11c+ cells,
48 hr after injection of diphtheria toxin (DT) into CD11c.diphtheria
toxin receptor (DTR) mice bearing subcutaneous B16 tumors. Tu-
mors were digested 17 days post-injection, at which point they had
reached approximately 75 mm2. To identify tumor cDCs by ﬂow cy-
tometry, we excluded Ly6C+ monocytes, and analyzed CD11c+
MHCII+ cells, which were either F4/80neg or CD64neg (Figures 1A
and 1B). Expression of CD24 distinguishes conventional cells from
monocyte-derived cells.17 Within the CD24low to high cDC population,
cDC1 were deﬁned by expression of CD103+ and high levels of CD24,
while CD11b+ cDC2 expressed low to intermediate levels of CD24
(Figure 1C). Therefore, to include both populations, we used a broad
CD24 gate in this study. Figures 1A–1D show that cDCs in B16 tu-
mors were largely comprised of cDC2, with cDC1 representing a
smaller subset, in agreement with published data.18 Injection of DT
into CD11c.DTR recipients led to the depletion of all CD11c+ cDCs
from the spleen within 48 hr (Figure 1E). To objectively assess the
impact of DT on tumor immune cells, we exploited an unsupervised
analysis using multidimensional reduction analysis of ﬂow cytometryfrom >3 independent experiments. (F) Nonlinear dimensionality reduction analysis of CD
the parameters CD11c, MHCII, Ly6C, CD103, CD24, CD11b, and F4/80, and colors ind
are pooled from 4 samples from 1 representative experiment. The red circle marks the c
contour plots showing tumor cDCs 48 hr post-injection of DT and (H). Summary bar gdata. Figure 1F shows viSNE maps, which allow visualization of the
data derived from the t-distributed stochastic neighbor embedding
(t-SNE) algorithm.19 Here, pre-deﬁned myeloid cell populations
were overlaid onto the t-SNE plot for total CD45+ cells. Using this
analysis, cDC1 could be distinguished as a distinct cluster of cells,
which was lost from tumors in DT-treated mice, (Figure 1F, see red
circled population). By comparison, cDC2 and macrophages were
displayed as merged clusters and appeared less affected by a single
injection of DT (Figure 1F, gray circles). Analysis of the relative fre-
quencies of these populations within CD45+ cells using ﬂow cytomet-
ric plots demonstrated that cDC1 were highly sensitive to a single in-
jection of DT, while cDC2 were not depleted. We observed a trend
toward depletion of F4/80+ macrophages after DT injection (Figures
1G and 1H). Having characterized baseline responses to DT, we
subsequently investigated whether these changes in the endogenous
tumor myeloid compartment affected the number and function of
adoptively transferred TCR-engineered T cells.
Depletion of CD11c+ Cells from CD11c.DTR Chimeras Leads to
Enhanced Accumulation of Activated TCR-Engineered T Cells
To test a requirement for CD11c+ cells, in particular cDC1, on adop-
tively transferred tumor-speciﬁc T cells, we established a model
of adoptive cell therapy (ACT) in which CD8+ T cells were engineered
to express the anti-melanoma TCR, which recognizes TRP-2181–188
presented by H2-Kb.20 Murine CD8 T cells were activated by ConA
and IL-7 and transduced with a retroviral vector encoding the
TRP-2-speciﬁc TCR (Figure 2A). Transduced T cells were peptide
speciﬁc and recognized B16 tumor cells expressing TRP-2 endoge-
nously, but not H2-Kb+ EL4 tumors that did not express TRP-2 (Fig-
ures 2B and 2C). 4 106 CD8+ Thy1.1+ T cells, containing on average
1.8 106 ± 0.2 106 (SEM) TRP-2-speciﬁc T cells, were transferred,
without preconditioning, to mice bearing established B16.F10 tu-
mors. This resulted in the antigen-speciﬁc accumulation of trans-
ferred T cells in vivo (Figure 2D). Transferred T cells were identiﬁed
by expression of the congenic marker Thy1.1, the reporter gene
CD19, and the TRP-2-speciﬁc Vb3 chain. After transfer, TRP-2-spe-
ciﬁc T cells accumulated within B16 tumors. For example, before in-
jection, approximately 40% of transferred T cells expressed the TRP-2
TCR, and, 12 days after adoptive transfer, this frequency was largely
unchanged in the spleen of recipient mice. In contrast, the analysis of
tumor-inﬁltrating lymphocytes showed that >90% of adoptively
transferred Thy1.1+ T cells in the tumor expressed the TRP-2 TCR,
indicating selective enrichment of TCR-expressing T cells in the
tumor microenvironment (Figure 2E).
The activity of the CD11c promoter in CD11c.DTR transgenic mice
leads to aberrant expression of the DTR in the brain and gut, leading
to death of these mice after repeated injections of DT.21,22 To bypass45+ cells in d17 tumors 48 hr after injection of PBS or DT. t-SNE maps are based on
icate overlays of different populations as shown in (A), on the tSNE coordinates. Data
DC1 cluster, while gray circles highlight cDC2 and macrophages. (G) Representative
raph of the data (±SD). p = 0.008; n = 8, from three independent experiments.
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Figure 2. T Cells Engineered to Express TRP-2 TCRs
Accumulate in B16 Tumors
(A) A schematic showing the retroviral vector containing the
TRP-2-TCR construct composed of Va12.1 and Vb3 TCR
chains separated by a 2A sequence. CD19 with a trun-
cated endodomain was used as a marker of transduction.
LTR, long-terminal repeat;c, retroviral packaging element;
IRES, internal ribosome entry site. (B) CD8+ TRP-2-TCR-
transduced (CD19+) splenocytes were co-cultured over-
night with TRP-2181–188 peptide, irrelevant peptide, or
unloaded RMA/S cells. The line graph shows the mean
frequency (±SD) of intracellular IFN-g+-transduced T cells.
(C) TRP-2-TCR-transduced T cells were co-cultured
overnight with irradiated B16.F10 (tumor antigen positive)
or EL4 (antigen negative) tumors. The bar chart shows a
summary of the mean frequency (±SD) of IFN-g+-trans-
duced T cells, p = 0002. Data for (B) and (C) are pooled
from 3–4 independent experiments, n = 4. (D) Represen-
tative dot plots show the gating strategy for identification of
transferred (CD8+ Thy1.1+) lymphocytes from the tumor.
Cells are pre-gated on live, single CD45+ cells. TRP-2-
TCR-transduced cellswere further identified by expression
of CD19 or Vb3. Mock transduced cells were cultured
without the addition of retrovirus. (E) Summary bar graph
showing the mean frequency (±SD) of transduced cells
(based on Vb3 expression) from in vitro cells before injec-
tionor from theCD8+Thy1.1+ cells isolated from the spleen
or tumor 13 days post-transduction, n = 4 (in vitro) or
n = 11/13 (spleen/tumor, respectively). In vitro cells versus
tumor and spleen versus tumor. p < 0.0001. Data are
from three independent experiments. ***p < 0.001.
Molecular Therapythis effect, syngeneic chimeras are routinely generated in which the
DTR transgene is restricted to the hematopoietic system. Therefore,
to test the impact of the loss of CD11c+ cells on TRP-2-expressing
T cells, we transferred TRP-2 TCR-engineered T cells into tumor-
bearing established CD11c.DTR/B6 chimeras and depleted
CD11c+ cells by injection of DT from 1 day before until 5 days after
T cell transfer (Figure 3A). Mice were sacriﬁced 8 days after the last
injection of DT. Figure 3B shows that injection of DT led to an in-
crease in the relative frequency of adoptively transferred T cells in tu-
mors. However, we observed that endogenous T cells in B16 tumors
expressed high levels of CD11c, which might result in their depletion
after DT treatment (Figure 3C). Local depletion of endogenous
CD11c+ T cells could trigger a lymphopenia-induced expansion of
the adoptively transferred DT-insensitive T cells. Therefore, in order
to control for this possibility, we repeated our experiments by gener-
ating CD11c.DTR.Rag2/ mice and using bone marrow (BM) from
these mice to generate syngeneic chimeras. Figure 3D demonstrates
that DT-mediated depletion of CD11c+ cells from mice lacking
DT-sensitive endogenous T cells also led to a relative increase in
the frequency of transferred T cells in the tumor, but not spleen
and LN. These data indicated that the accumulation of transferred
T cells in the tumor microenvironment after DT treatment was not
driven by the local depletion of endogenous T cells.
We further explored whether DT treatment affected the phenotype
of the adoptively transferred T cells in the tumor. Figure 3E shows1474 Molecular Therapy Vol. 26 No 6 June 2018that the transferred T cells in the tumors of DT-treated recipients
expressed lower levels of CD62L compared to PBS-treated
controls, suggesting that depletion of CD11c+ cells was associated
with a more differentiated CD62Lneg phenotype of TCR-engineered
T cells.
Therefore, together, these data demonstrate that loss of myeloid
CD11c+ cells leads to an enhanced accumulation of differentiated
tumor-speciﬁc T cells within the tumor bed by mechanisms that
are independent of endogenous lymphocytes.
Depletion of cDCs Does Not Result in Accumulation of
Monocytes within Tumors
Depletion of cDCs results in monocytosis and neutrophilia due to
increased levels of serum granulocyte colony-stimulating factor
(G-CSF).23–25 Therefore, to test whether increased numbers of mono-
cytes (or monocyte-derived cells) could impact the accumulation of
TRP-2 T cells, we analyzed the frequency of monocytes in the tumors
of DT-injected mice. Figures 4A and 4B show that, despite a clear in-
crease in the frequency of monocytes and neutrophils in the spleens of
DT-injected CD11c.DTR chimeras, these cells did not accumulate in
B16 tumors. These data are consistent with our previous ﬁnding that
circulating monocytes did not migrate to the skin after depletion of
cDCs.24 Therefore, these experiments demonstrate that the monocy-
tosis and neutrophilia induced post-depletion of CD11c+ cells
does not impact the local tumor environment, and, therefore, that
Figure 3. Depletion of CD11c+ Cells Leads to
Enhanced Expansion of Tumor-Specific T Cells
(A) Schematic showing the experiment. CD11c.DTR or
CD11c.DTRxRag2/ into syngeneic C57BL/6 chimeras
were established and injected s.c. with B16.F10 cells.
Mice were depleted of CD11c+ cells by injection of 100 ng
DT on days 6, 9, and 12. 1 day after the first dose of DT,
mice also received 4  106 Thy1.1+ CD8+ T cells that had
been transduced with the TRP-2 TCR. Mice were sacri-
ficed on day 20, and transferred cells were analyzed in
spleens, LNs, and tumors. (B) Summary bar graph
showing the fold change in frequency of tumor-infiltrating
Thy1.1+ T cells from total CD8 in DT-treated CD11c.DTR
chimeras (gray) compared to the mean of the PBS control
group (white) (±SD). p = 0.0156; n = 8 from two inde-
pendent experiments. (C) Bar graph showing median
CD11c fluorescent intensity (±SD) on CD4+ or CD8+
lymphocytes. CD8 spleen versus LN and spleen versus
tumor p = 0.0001; LN versus tumor p = 0.005. CD4 spleen
versus LN p = 0.001; spleen versus tumor p = 0.002; LN
versus tumor p = 0.05; n = 7 from two independent ex-
periments. (D) Summary bar graph showing fold change in
frequency (±SD) of Thy1.1+ T cells from the total CD8 in
CD11c.DTR.Rag2/ chimeras after treatment with DT
(gray) or PBS (white). Tumor p = 0.0018; n = 15-19, from
four independent experiments. (E) Left: representative
histogram overlay showing expression of CD62L by tu-
mor-infiltrating Thy1.1+ T cells in DT- or PBS-treatedmice.
Right: summary bar graph showing median CD62L fluo-
rescence intensity (±SD) after treatment with PBS or DT.
p = 0.0027; n = 12–15 from three independent experi-
ments. *p < 0.05; **p < 0.01; ***p < 0.001.
www.moleculartherapy.orgexpansion of T cells cannot be explained by an increase in tumor
monocytes.
Depletion of CD11c+ Cells Re-sets the Tumor cDC Niche
In the experiments described above, mice were sacriﬁced 8 days after
the last injection of DT (Figure 3A), during which time the DC niche
would be expected to be repopulated by BM-derived cells.22 There-
fore, we questioned whether emerging cDCs, which have not yet
been subverted by the tumor microenvironment, might mediate
expansion of tumor-speciﬁc T cells. To address this hypothesis, we
ﬁrst characterized the tumor myeloid compartment 1 week after the
last injection of DT. Figure 5A shows B16 tumors are repopulated
by cDCs after termination of DT treatment. Analysis of the frequency
of repopulating cells demonstrated that tumors previously depleted of
CD11c+ cells contained an increased frequency of cDC1 and cDC2
because of an increase in cells within the CD24low to highCD64neg total
cDC gate (Figure 5B). Total numbers of cDCs were also increased
following repopulation of DT-treated tumors, but we found large
variability in cDC numbers between experiments, and these differ-
ences did not reach statistical signiﬁcance (Figure 5C). This response
was speciﬁc to the cDC niche because we did not observe an increasein monocyte or macrophage populations in repopulating tumors
(Figure 5C).
To test whether newly recruited cDC1 had the potential to activate re-
cruited TRP-2 TCR-transduced T cells, we investigated whether repo-
pulating cDC1 cross-presented endogenous tumor antigen to TRP-2
T cells. Thus, we puriﬁed CD11c+ cells from tumors growing in
CD11c.DTR chimeras 1 week after the last injection of PBS or DT.
Isolated CD11c+ cells were cultured with freshly transduced TRP-2
T cells, which were assessed 18 hr later for antigen-speciﬁc interferon
g (IFN-g) production. Figure 5D shows that there was no difference
in the ability of TRP-2 T cells to produce IFN-g in response to pep-
tide-pulsed cells from either PBS- or DT-treated mice, suggesting no
overt intrinsic differences between resident and repopulating cDCs.
However, in the absence of exogenous antigen, puriﬁed cDCs from
DT-treatedmice weremore effective in stimulating IFN-g production
of TRP-2-speciﬁc T cells, suggesting improved presentation of natu-
rally processed peptide.
Therefore, together, these data suggest that depletion of CD11c+ cells
drives the recruitment and/or expansion of cDCs in B16 tumors, andMolecular Therapy Vol. 26 No 6 June 2018 1475
Figure 4. Depletion of CD11c+ Cells Does Not Lead to Accumulation of
Tumor Monocytes
Left: representative dot plots showing gating of CD11b+Ly6Cint neutrophils and
CD11b+Ly6Chigh monocytes in the spleen (A) and B16 tumor (B) of control mice.
Plots are pre-gated on live CD45+ cells. Right: bar graph showing mean frequencies
(±SD) of cells in the spleen (A) and tumor (B) site on day 14, 48 hr after the last
injection of DT. Splenic neutrophils p = 0.007, monocytes p = 0.0001; n = 4 (spleen)
or 8 (tumor) from three independent experiments. **p < 0.01; ***p < 0.001.
Molecular Therapythat repopulating cDC1 process and cross-presents tumor antigen to
TRP-2 T cells.
Injection of DT Depletes a Population of EGFP+ Tumor
Macrophages from B16 Tumors
The aberrant activity of the CD11c.DTR transgene can lead to DT-
mediated deletion of unexpected cell types outside the DC lineage.
The transgenic construct that was used to generate the CD11c.DTR
mice contains EGFP as a reporter gene.26 This provides an opportu-
nity to identify cells in which the CD11c.DTR construct is active,
which may render them susceptible to DT-mediated deletion. We,
therefore, analyzed in detail the EGFP expression proﬁle of hemato-
poietic cells present in B16 tumors. Comparison of endogenous
CD11c expression and CD11c.DTR EGFP transgene expression
demonstrated clear differences in the expression proﬁles of tumor
myeloid cells (Figure 6A). Thus, while cDC1 and cDC2 expressed
similarly high levels of endogenous CD11c, the EGFP expression
was remarkably different, with high levels in cDC1 and low levels
in cDC2. This correlated with the previously described differential
sensitivity of the two cDC subsets to depletion with DT (Figure 1).
Although all macrophages expressed high levels of endogenous
CD11c, a substantial proportion was negative for EGFP expression.
This observation explained the resistance of some tumor macro-1476 Molecular Therapy Vol. 26 No 6 June 2018phages to DT in these mice (Figure 1). In Figure 6B, 8.5% ± 0.64%
(SEM) of live CD45+ tumor-inﬁltrating cells expressed EGFP, and
injection of DT reduced this to 3.3% ± 0.43% (n = 4). Flow cyto-
metric analysis of cells remaining within the CD45+EGFP+ gate after
treatment with DT demonstrated that, while EGFP+ cDC1 and
macrophages were efﬁciently ablated, EGFP+ cDC2 and monocytes
appeared unaffected and remained in the tumor (Figures 6B
and 6C). Therefore, this analysis revealed differences in the activity
of the DTR transgene within different CD11c+ populations and
demonstrated the preferential loss of a subset of EGFP+ DT-sensitive
macrophages. Further analysis did not reveal any phenotypic differ-
ences between macrophages expressing high or low levels of EGFP.
However, staining for the immunosuppressive ligand programmed
death-ligand (PD-L)-1 demonstrated that tumor macrophages ex-
pressed high levels of this molecule (Figure 6D). Therefore, these
data suggest that depletion of local tumormacrophages, in the context
of the augmented cDC1 niche, may contribute to the expansion of
transferred T cells in DT-treated mice.
DISCUSSION
TCR gene therapy is a potent therapeutic strategy for cancer, lead-
ing to durable cancer regression in some patients in the absence of
some of the toxicities caused by other T cell immunotherapies.
Transfer of in vitro-activated TCR-transduced T cells bypasses a
requirement for priming by the patient’s endogenous cDCs. How-
ever, it was not clear whether interactions between transferred
effector T cells and cDCs within the tumor were required or, indeed,
sufﬁcient for the expansion and survival of therapeutic T cells. Here,
we show that tumor cDC1 can engage TCR-engineered T cells and
contribute to their expansion in the tumor microenvironment. But
this occurs in the context of local macrophages, which have the po-
tential to cause suppression of T cell function. Together, these data
demonstrate the importance of endogenous myeloid cells within the
tumor microenvironment in regulating recruited TCR-gene-modi-
ﬁed T cells.
cDC1 are specialized cross-presenting cells and are highly immuno-
genic within the tumor environment.5,8 We have previously exploited
the temporal depletion of CD11c+ cells from CD11c.DTR mice to
demonstrate the potency of repopulating cDCs in LNs to cross-pre-
sent lentiviral antigen in a vaccination immunotherapy model.22
Here, we demonstrated that repopulation of cDCs within the tumor
microenvironment resulted in the relative augmentation of both tu-
mor cDC1 and cDC2 populations. This was associated with enhanced
presentation of endogenous tumor antigens to TRP-2 TCR T cells
and increased accumulation of more differentiated CD62Lneg TCR-
engineered T cells. However, we also observed depletion of some
tumor-resident macrophages that potentially expressed higher levels
of the inhibitory ligand, programmed death ligand (PD-L) 1, than
other myeloid populations. Therefore, together, our data suggest a
working model in which cDC1 engage inﬁltrating engineered
T cells to promote differentiation and expansion in the tumor micro-
environment, but these interactions occur in the context of inhibitory
signals from local macrophages and, possibly, other myeloid cells. In
Figure 5. Depletion of CD11c+ Cells Results in
Enhanced Accumulation of Tumor cDCs
(A) Representative contour plots showing myeloid cell
populations in B16 tumors 1 week after the last injection of
DT (see also schematic in Figure 3). Plots were pre-gated
on live, single CD45+Ly6cneg cells. (B) Bar graph shows
summary mean frequency (±SD) of cDCs, cDC1, or cDC2
of total CD45+ cells on day 19 in PBS- (white) or DT-
treated (gray) recipients. PBS versus DT cDCs p = 0.009,
cDC1 p = 0.005, cDC2 p = 0.04. (C) Bar graphs showing
the mean number of cells (±SD) 1 week post-PBS or -DT.
n = 16–18 from four independent experiments for fre-
quency and numbers. (D) Bar charts showing the mean
frequency (±SD) of intracellular IFN-g+ cells from CD8+
TRP-2-TCR-transduced (CD19+) splenocytes. Cells were
cocultured with peptide-pulsed or non-peptide-pulsed
tumor-derived CD11c+ cells sorted on day 19. n = 3
per group, one representative experiment shown of two
independent experiments. *p < 0.05; **p < 0.001.
www.moleculartherapy.orgsupport of this model, Wrzesinski et al.27 demonstrated that trans-
plantation of hematopoietic stem cells into irradiated mice resulted
in expansion of transferred in vitro-activated CD8 T cells, but this
was not sufﬁcient to mediate tumor rejection in the absence of mye-
loablative conditioning to remove endogenous regulatory cells. We
also found that, while recruited cDCs enhanced T cell numbers and
activation within tumors, it was not sufﬁcient to enhance tumor rejec-
tion in the poorly immunogenic B16 model (C.L.B. and H.J.S., data
not shown).
Pre-DCs are recruited to tumors,28 and it has recently been shown
that the growth factors that control cDC development in the tissues
are also required for development of the tumor-resident DC compart-
ment.8 However, melanomas evolve intrinsic mechanisms, such
as increased signaling via b-catenin or secretion of prostaglandin
E2 (PGE2), to selectively block recruitment of cDC1.
9,18 Our work
suggests that, in addition to these tumor-intrinsic mechanisms, the
tumor hematopoietic compartment also determines the composition
of resident myeloid cells, and this can be re-set upon depletion of
CD11c+ cells. The mononuclear phagocytic system is a highly dy-
namic cellular compartment with the plasticity to rapidly respond
to changing levels of circulating growth factors. Depletion of
CD11c+ cells has been shown to result in a rapid increase in myeloid
serum growth factors, including G-CSF and fms-like tyrosine kinase
(Flt) 3 ligand.29 Under these conditions, repopulation by DCs is pre-
ceded by a transient monocytosis in the BM, blood, and spleen, but
not the skin.24 Our data indicate that systemic changes to myeloid
growth factors do not lead to accumulation of monocytes or neutro-
phils within B16 tumors, but they suggest the possibility that local
alteration of the tumor microenvironment, for example, due to a
loss of immunosuppressive macrophages, regulates the populationMoof the tumor cDC niche. Thus, we propose
that, during normal growth, regulation of
engineered T cells by tumor macrophages maydominate. However, interventions to alter the population dynamics,
such that new cDC1 are recruited into the tumor, may shift this
balance to enhance T cell accumulation.
Vaccination is essential for the therapeutic efﬁcacy of gene-modiﬁed
T cells in a prostate cancer model,30 and this, with observations that
TCR-transduced T cells are detected in the draining, but not the
non-draining LNs of tumor-bearing recipients,31 has led to an
assumption that gene-modiﬁed T cells require stimulation by
cDCs in vivo to enhance their therapeutic activity.32 However, these
data focus on the role of cDCs in lymphoid organs, and the site of
cDC-T cell interaction in tumor-bearing recipients has not been
carefully investigated. Our data demonstrate that in vitro-activated
T cells preferentially accumulate in tumors, but not LNs or spleen,
inferring a role for local interactions with tumor-resident myeloid
cells. Recent data have suggested that anti-tumor activity by adop-
tively transferred cytokine-activated TCR transgenic T cells depends
on recruitment of cDC1 to tumors.9 We show that baseline recruit-
ment of engineered T cells that have been activated in vitro via their
TCRs was not impaired in the absence of cDCs. Together, these
studies highlight the importance of cDC1 for T cell immunotherapy,
but they reveal potential differences in the nature of the interactions
between endogenous cDCs and the different types of T cells used
for ACT.
Gene-engineered therapies using T cells that express tumor-speciﬁc
TCRs or CARs have shown success in blood cancers, but their poten-
tial in solid tumors has hampered the immunosuppressive microen-
vironment. We and others have demonstrated that genetic modiﬁca-
tion of TCR constructs to enhance functional avidity may augment
T cell ﬁtness within the tumor,33–36 but the therapeutic potential oflecular Therapy Vol. 26 No 6 June 2018 1477
Figure 6. CD11c.DTR-Linked Reporter EGFP Expression Identifies a Subset of Tumor-Resident Macrophages that Are Sensitive to DT
(A) Representative histograms showing expression of EGFP or CD11c expression in tumor myeloid populations of control CD11c.DTR mice. Histogram counts are
normalized to mode. (B) Representative contour plots showing gating of live, single CD45+ cells 48 hr after a single injection of PBS or DT. (C) Bar graph showing the
frequency (±SD) of gated cells within the EGFP+ population either in PBS controls or the non-depleted EGFP+ cells in DT-treated mice. Mono., monocyte; Macs, macro-
phages (CD64+). PBS versus DT cDC1 p = 0.0099; macrophages p = 0.0176; n = 4 from one experiment. (D) Left: representative histograms of PD-L1 expression onmyeloid
cells within B16 tumors. Right: bar chart showing median PD-L1 fluorescence (±SD). cDC1 versus macrophages p = 0.05; n = 5 from two independent experiments.
*p < 0.05, **p < 0.01.
Molecular Therapythese cells is limited by factors that control recruitment, survival, and
activation of tumor-inﬁltrating T cells. Our ﬁndings on the impor-
tance of tumor cDCs have clinical implications for their targeted acti-
vation to enhance engineered T cell function within the tumor envi-
ronment. One possibility is that this would also augment tumor
antigen spread by DCs to broaden the activation of endogenous
anti-tumor T cells, as has recently been shown after administration
of a combination therapy for large established B16 melanomas.37
The data presented here highlight the importance of the balance be-
tween beneﬁcial and inhibitory interactions with endogenous
myeloid cells to control expansion of engineered T cells within the
tumor microenvironment and point toward future strategies that
manipulate endogenous myeloid cells to promote therapeutic re-
sponses to solid organ tumors.1478 Molecular Therapy Vol. 26 No 6 June 2018MATERIALS AND METHODS
Mice and Tumor Injection
Animals were used under protocols approved by local institutional
research committees and in accordance with UK Home Ofﬁce
guidelines. C57BL/6 (B6) mice were bred in-house. Homozygous
CD11c.DTR (B6.FVB-Tg(Itgax-DTR/ EGFP)57Lan/J) mice were
bred in-house. Rag2/ mice were bought from Jackson Labora-
tory and crossed in-house to CD11c.DTR mice. CD11c.DTR
and CD11c.DTR.Rag2/ syngeneic chimeras were generated as
described previously.38 CD11c+ cells were depleted upon intraperito-
neal injection of 100 ng of DT (Sigma, UK) in PBS according to
published protocols. Chimeras received single injections or repeated
injections once every 72 hr, and depletion was assessed in control
animals 24–48 hr after injection of DT.
www.moleculartherapy.orgB16.F10 melanoma cells were cultured in RPMI 1,640 medium
(Lonza), supplemented with 10% fetal calf serum (FCS; Biosera),
1% L-glutamine (2 mM), and 1% penicillin/streptomycin
(100 U/mL). C57BL/6 mice were injected subcutaneously with
1  105 B16.F10 cells in 100 mL of PBS. Tumors became palpable
by days 5–10. Tumor size was assessed using calipers every
2–3 days. Mice were euthanized if tumors grew to >15 mm in any
direction, as per home ofﬁce regulations.
Generation of TRP-2 TCR-Transduced T Cells
The TRP-2 TCR, which recognizes TRP-2181–188, was a kind gift from
Professor Ton Schumacher (Netherlands Cancer Institute) and was
cloned into the retroviral vector pMP71 with a 2A sequence sepa-
rating the Va12.1 and Vb3 chains, followed by an internal ribosome
entry site (IRES) truncated CD19 sequence.39 The TCR was codon
optimized and also contains an extra cysteine residue in the constant
chains to enhance pairing of the a and b chains.40,41
To generate TRP-2 retroviral particles, Phoenix-Eco (PhEco)-
adherent packaging cells (Nolan Laboratory) were transiently trans-
fected with retroviral vectors for the generation of supernatant con-
taining the recombinant retrovirus required for infection of target
cells, as described previously.33 The PhEco-adherent packaging
cells were transfected using Fugene HD (Roche) with the pCL-eco
construct and the TRP-2 TCR vector according to the manufacturers’
instructions. CD8+ T cells were puriﬁed from C57BL/6 splenocytes by
magnetic selection according to the manufacturer’s instructions (Mil-
tenyi Biotec). Sorted cells were activated with concanavalin (Con) A
(2 mg/mL) and IL-7 (1 ng/mL) for 24 hr, and then 4–6 106 activated
T cells were incubated for a further 24 hr with retroviral particles on
retronectin-coated (Takara-Bio) 6-well plates, in the presence of IL-2
(100 U/mL; Roche). Transduced cells were injected intravenously into
mice 24 hr after transduction.
Lymphocyte Isolation from Tumors
Tumor samples were mechanically digested using dissection scissors
before culturing in 1 mL of RPMI containing 320 mg of Liberase TL
(Roche) and 200 mg of DNase 1 grade 2 (Roche). These were incu-
bated at 37C in a shaking incubator for 30 min. Tumor leukocytes
were then isolated as interphase cells after centrifugation with Histo-
paque-1077 (Sigma-Aldrich).
Flow Cytometry
The following monoclonal antibodies were used to stain cells:
anti-CD11b v450, F4/80 APCeFluor780, Ki67 eFluor660, CD19
PerCpCy5.5, Thy1.1 PeCy7 (eBiosciences), CD11c ﬂuorescein isothio-
cyanate (FITC) or allophycocyanin (APC), CD24BV711,CD45.2 v500,
CD103 biotin, I-Ab phycoerythrin (PE), Ly6C PeCy7, PD-L1 APC,
streptavidin PerCpCy5.5, CD4 APC-H7, CD8 v450, CD62L Alexa700,
IFN-g APC, Vb3 PE (BD Biosciences), or CD64 PE (BioLegend).
Exclusion of propidium iodide was used to gate live cells. Cells were
enumerated using CountBright absolute counting beads (Thermo
Fisher Scientiﬁc). Sampleswere acquiredusing theFortessaﬂowcytom-
eter (BD Biosciences) and analyzed using FlowJo software (Treestar).Multidimensional Reduction Analysis
The automated t-SNE algorithm was used to visually analyze ﬂuores-
cence-activated cell sorting (FACS)-stained lymphocytes (viSNE).19
This was performed using the Cytobank online platform.42 Cells
were pre-gated on live (PI) CD45+ cells before analysis. Deﬁned
populations were then characterized by conventional FACS analysis
and overlaid over the viSNE coordinates where indicated.
T Cell Restimulation Assay
RMA/S cells are a transporter associated with antigen processing
(TAP)-deﬁcient derivative of the RMA cell line that can efﬁciently
present exogenously loaded peptide. TRP-2-TCR-transduced T cells
were rested for 5 days post-transduction, then stimulated with
peptide loaded cells. To stabilize empty major histocompatibility
(MHC) molecules, 1  106 RMA/S cells were cultured overnight
at 20C. The next day, RMA/S cells were incubated with 10 mM–
100 pM of relevant (TRP-2181–188: VYDFFVWL) or irrelevant
(gp10025–33: EGSRNQDWL) peptide at 37C for 3 hr. RMA/S cells
were then irradiated with 80 Gy and washed in complete RPMI,
and 1  105 cells were plated in a 96-well plate for 18 hr with
1  105 TRP-2 TCR-transduced T cells. Intracellular IFN-g was
detected in transduced T cells using the BD Perm/ﬁx kit with
brefeldin A according to the manufacturer’s instructions (BD Biosci-
ences) and stained with anti–IFN-g antibody (BD Biosciences). Alter-
natively, 1  105 irradiated (80 Gy) B16.F10 or EL4 tumor cells were
cocultured overnight with 1  105 TRP-2 TCR-transduced T cells,
and IFN-g expression was assessed as indicated above.
Restimulation with Tumor CD11c+ Cells
CD11c+ cells were positively selected from tumor leukocytes by incu-
bation with murine anti-CD11c MicroBeads and two MS magnetic
separation columns (Miltenyi). CD11c+ cells were peptide loaded,
or not, with 1 mM relevant peptide (TRP-2181–188: VYDFFVWL) for
2 hr, then washed and plated in a 96-well plate. 1  104 CD11c+
cells were cocultured overnight with 1  105 TRP-2TCR-transduced
T cells. After 18 hr, cells were incubated with brefeldin A
(eBioscience) and stained for intracellular IFN-g as indicated above.
Statistical Analysis
Statistical comparisons were made by using a two-tailed Student’s
t test for parametric data, a two-tailed Mann-Whitney U test for
non-parametric data, and a Wilcoxon signed rank test for comparing
relative values to the mean of the control.
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